Angott Medical Products, a Bloomfield Hills, Michigan-based start up that is developing breast cancer testing technology, has received funding from the Michigan Pre-Seed Capital Fund.
The company intends to use the funds, whose amount was not disclosed, for its commercialization efforts.
Led by President Paul Angott, Angott Medical Products has developed a non-invasive, comfortable, radiation-free, medical device to screen for breast cancer (BC). The tester captures data digitally and analyze the results in software, eliminating the need for a highly trained specialist to interpret the results.
The funding is part of a $2m investment made by the Michigan Pre-Seed Capital Fund in nine companies. It operates as an equity investment vehicle that receives the same returns as the third party investor, which are then redeployed as first round capital to Michigan-based start-ups.